Rapid-Acting Insulin Now Approved for Use With Pumps


By: Radha McLean

NovoLog (insulin aspart) has received supplemental approval from the U.S. Food and Drug Administration for use in external insulin pumps, Novo Nordisk Pharmaceuticals announced in December 2001. This decision, according to Novo Nordisk, makes NovoLog the only rapid-acting insulin analog to be indicated for use with pumps.

Eli Lilly tells Diabetes Health that it expects FDA approval for Humalog use in pumps later this year.



Diabetes Health Medical Disclaimer
The information on this site is not intended or implied to be a substitute for professional medical advice, diagnosis or treatment. All content, including text, graphics, images, and information, contained on or available through this website is for general information purposes only. Opinions expressed here are the opinions of writers, contributors, and commentators, and are not necessarily those of Diabetes Health. Never disregard professional medical advice or delay seeking medical treatment because of something you have read on or accessed through this website.